文献速递肝病

选择性靶向赖氨酰氧化酶样蛋白2(LOXL2)可抑制肝纤维化进展并加速其逆转

Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.
PubMed 文献 · Gut · 2017-01-10

研究探讨LOXL2在胶原交联和肝祖细胞(HPC)分化中的作用,以及抗LOXL2单克隆抗体对小鼠肝纤维化进展与逆转的疗效。在硫代乙酰胺(TAA)诱导的纤维化进展期或恢复期给药,并在胆汁性纤维化模型中验证。结果显示LOXL2在纤维化肝脏中强诱导,抗LOXL2治疗显著减少胶原交联和桥接纤维化,促进纤维化逆转,并直接促进HPC向肝细胞分化。

要点

  • LOXL2在健康肝脏中几乎不表达,在纤维化肝脏中强诱导并主要定位于纤维化间隔。
  • 延迟抗LOXL2治疗显著减少TAA诱导的胶原交联和桥接纤维化,形态学胶原沉积减少53%。
  • 在已建立的TAA纤维化中,LOXL2抑制促进纤维化逆转,恢复4周时胶原面积减少45%。

核心结论

  • LOXL2介导肝纤维化过程中的胶原交联和纤维化基质稳定,并独立促进促纤维化HPC分化。
  • 通过阻断这两条汇聚的促纤维化通路,治疗性LOXL2抑制可减轻实质性和胆汁性纤维化并促进纤维化逆转。

研究设计与样本

  • 研究在小鼠中进行,抗LOXL2抗体、对照抗赖氨酰氧化酶抗体或安慰剂在TAA诱导的纤维化进展期或恢复期给药。
  • 在BALB/c.Mdr2-/-小鼠和3,5-二乙氧基羰基-1,4-二氢可力丁(DDC)喂养小鼠中测试胆汁性纤维化的疗效。
  • 体外研究原代EpCAM(+)肝细胞中HPC分化。

主要发现

  • LOXL2在健康肝脏中几乎不表达,在纤维化肝脏中强诱导,主要定位于纤维化间隔。
  • 延迟抗LOXL2治疗活动性TAA纤维化显著减少胶原交联和桥接纤维化的组织学征象,形态学胶原沉积减少53%。
  • 在已建立的TAA纤维化中,LOXL2抑制促进纤维化逆转,纤维化间隔增强分裂和变薄,恢复4周时胶原面积减少45%。
  • 在Mdr2-/-和DDC诱导的胆汁性纤维化模型中,抗LOXL2抗体同样取得显著抗纤维化疗效并抑制胆管反应,同时肝细胞复制增加。
  • 阻断LOXL2对体外原代EpCAM(+) HPC行为有深刻直接效应,促进其向肝细胞分化,同时抑制胆管细胞谱系定向。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: We studied the role of lysyl oxidase-like 2 (LOXL2) in collagen crosslinking and hepatic progenitor cell (HPC) differentiation, and the therapeutic efficacy of a LOXL2-blocking monoclonal antibody on liver fibrosis progression/reversal in mice. METHODS: Anti-LOXL2 antibody, control antilysyl oxidase antibody or placebo was administered during thioacetamide (TAA)-induced fibrosis progression or during recovery. Therapeutic efficacy in biliary fibrosis was tested in BALB/c.Mdr2-/- and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-fed mice. Collagen crosslinking, fibrosis progression and reversal were assessed histologically and biochemically. HPC differentiation was studied in primary EpCAM(+) liver cells in vitro. RESULTS: LOXL2 was virtually absent from healthy but strongly induced in fibrotic liver, with predominant localisation within fibrotic septa. Delayed anti-LOXL2 treatment of active TAA fibrosis significantly reduced collagen crosslinking and histological signs of bridging fibrosis, with a 53% reduction in morphometric collagen deposition. In established TAA fibrosis, LOXL2 inhibition promoted fibrosis reversal, with enhanced splitting and thinning of fibrotic septa, and a 45% decrease in collagen area at 4 weeks of recovery. In the Mdr2-/- and DDC-induced models of biliary fibrosis, anti-LOXL2 antibody similarly achieved significant antifibrotic efficacy and suppressed the ductular reaction, while hepatocyte replication increased. Blocking LOXL2 had a profound direct effect on primary EpCAM(+) HPC behaviour in vitro, promoting their differentiation towards hepatocytes, while inhibiting ductal cell lineage commitment. CONCLUSIONS: LOXL2 mediates collagen crosslinking and fibrotic matrix stabilisation during liver fibrosis, and independently promotes fibrogenic HPC differentiation. By blocking these two convergent profibrotic pathways, therapeutic LOXL2 inhibition attenuates both parenchymal and biliary fibrosis and promotes fibrosis reversal.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Ikenaga N, Peng ZW, Vaid KA, et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut. 2017. PMID: 28073888. doi:10.1136/gutjnl-2016-312473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。